A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children With Duchenne Muscular Dystrophy
Phase of Trial: Phase I/II
Latest Information Update: 16 Feb 2018
Price : $35 *
At a glance
- Drugs Givinostat (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Italfarmaco
- 04 Dec 2017 Status changed from active, no longer recruiting to completed.
- 23 Feb 2016 Planned End Date changed from 1 Aug 2015 to 1 Aug 2017, as reported by ClinicalTrials.gov.
- 02 Dec 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.